Skip to main navigation Skip to search Skip to main content

Colchicine, COVID-19 and hematological parameters: A meta-analysis

  • Musharraf Sarwar
  • , Zahid Ali
  • , Mahnoor Fatima
  • , Zouina Sarfraz
  • , Azza Sarfraz
  • , Ivan Cherrez-Ojeda
  • University College of Medicine and Dentistry
  • Kyrgyz State Medical Academy
  • Fatima Jinnah Medical University
  • Aga Khan University
  • Respiralab Research Group

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Introduction: Colchicine has the potential in reducing patient morbidity and mortality in COVID-19 infection owing to its anti-inflammatory properties. This study aims to determine the efficacy of colchicine in optimizing inflammatory hematological biomarker levels among COVID-19 patients. Methods: In accordance to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement guidelines, a systematic search was conducted using the following keywords: Colchicine, covid*, SARS-CoV-2, anti-inflammatory, trials, clinical, hematological, laboratory. Databases were searched from December 2019 until August 26, 2021: MEDLINE/PubMed, Web of Science, Cochrane, Scopus, and EMBASE. Other sources were located through ClinicalTrials.Gov, manually searching SAGE, Science Direct, Elsevier, and Google Scholar. The meta-analysis was conducted using Review Manager 5.4. Results: In total, six studies were included, of which four reported c-reactive protein (CRP) standardized mean reductions in the colchicine group (N = 165) as opposed to the control (N = 252; SMD = −0.49, p < 0.001). On noting lactate dehydrogenase (LDH) values post treatment, the colchicine group (N = 204) showed significant reductions at the end of treatment compared to control (N = 290; SMD = −0.85, p < 0.001). Finally, the D-dimer values in colchicine groups (N = 129) compared to control (N = 216) also documented a negative effect size (SMD = −0.9, p < 0.001). Conclusion: Colchicine has efficacy in reducing inflammatory biomarkers observed in moderate-to-severe COVID-19 patients. It may be worthwhile to consider monitoring the clinical and laboratory parameters of patients in further trials to consider colchicine as a strong candidate for an adjunct to COVID-19 treatment.

Original languageEnglish
Article numbere24057
JournalJournal of Clinical Laboratory Analysis
Volume35
Issue number12
DOIs
StatePublished - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • CRP
  • D-dimer
  • LDH
  • colchicine

Fingerprint

Dive into the research topics of 'Colchicine, COVID-19 and hematological parameters: A meta-analysis'. Together they form a unique fingerprint.

Cite this